IDNA vs. FHLC
Compare and contrast key facts about iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and Fidelity MSCI Health Care Index ETF (FHLC).
IDNA and FHLC are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. IDNA is a passively managed fund by iShares that tracks the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index. It was launched on Jun 11, 2019. FHLC is a passively managed fund by Fidelity that tracks the performance of the MSCI USA IMI Health Care Index. It was launched on Oct 21, 2013. Both IDNA and FHLC are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: IDNA or FHLC.
Key characteristics
| IDNA | FHLC | |
|---|---|---|
| YTD Return | 5.08% | 6.85% |
| 1Y Return | 2.13% | 12.29% |
| 3Y Return (Ann) | -18.61% | 5.40% |
| Sharpe Ratio | 0.05 | 1.11 |
| Daily Std Dev | 25.10% | 10.82% |
| Max Drawdown | -68.26% | -28.76% |
| Current Drawdown | -55.49% | -1.28% |
Correlation
The correlation between IDNA and FHLC is 0.67, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
IDNA vs. FHLC - Performance Comparison
In the year-to-date period, IDNA achieves a 5.08% return, which is significantly lower than FHLC's 6.85% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
IDNA vs. FHLC - Expense Ratio Comparison
IDNA has a 0.47% expense ratio, which is higher than FHLC's 0.08% expense ratio.
Risk-Adjusted Performance
IDNA vs. FHLC - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and Fidelity MSCI Health Care Index ETF (FHLC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
IDNA vs. FHLC - Dividend Comparison
IDNA's dividend yield for the trailing twelve months is around 0.99%, less than FHLC's 1.32% yield.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 0.99% | 1.04% | 0.54% | 0.70% | 0.26% | 0.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
FHLC Fidelity MSCI Health Care Index ETF | 1.32% | 1.40% | 1.30% | 1.16% | 1.45% | 1.18% | 2.13% | 1.37% | 1.39% | 2.06% | 1.03% | 0.20% |
Drawdowns
IDNA vs. FHLC - Drawdown Comparison
The maximum IDNA drawdown since its inception was -68.26%, which is greater than FHLC's maximum drawdown of -28.76%. Use the drawdown chart below to compare losses from any high point for IDNA and FHLC. For additional features, visit the drawdowns tool.
Volatility
IDNA vs. FHLC - Volatility Comparison
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) has a higher volatility of 6.54% compared to Fidelity MSCI Health Care Index ETF (FHLC) at 2.57%. This indicates that IDNA's price experiences larger fluctuations and is considered to be riskier than FHLC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.